Vaccine最新文献

{"title":"Corrigendum to Assessment of the Bnt162b2 covid-19 vaccine immune response in Brazilian indigenous adolescents. Vaccine Volume 43, Part 1, 1 January 2025, 126494","authors":"Laís Albuquerque de Oliveira , Isa Rita Brito de Morais , Silvana Beutinger Marchioro , Gabriel Barroso de Almeida , Gleyce Hellen de Almeida de Souza , Tiago da Silva Ferreira , Regina Rossoni , Dyjaene de Oliveira Barbosa , Vinicius João Navarini , Julio Croda , Alex José Leite Torres , Simone Simionatto","doi":"10.1016/j.vaccine.2024.126630","DOIUrl":"10.1016/j.vaccine.2024.126630","url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"45 ","pages":"Article 126630"},"PeriodicalIF":4.5,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Safety and Efficacy of inactivated COVID-19 vaccination in couples undergoing assisted reproductive technology: A prospective cohort study","authors":"Juan Yang ,&nbsp;Ying-Ling Yao ,&nbsp;Xing-Yu Lv ,&nbsp;Li-Hong Geng ,&nbsp;Yue Wang ,&nbsp;Enoch Appiah Adu-Gyamfi ,&nbsp;Xue-Jiao Wang ,&nbsp;Yue Qian ,&nbsp;Ming-Xing Chen ,&nbsp;Zhao-Hui Zhong ,&nbsp;Ren-Yan Li ,&nbsp;Qi Wan ,&nbsp;Yu-Bin Ding","doi":"10.1016/j.vaccine.2024.126635","DOIUrl":"10.1016/j.vaccine.2024.126635","url":null,"abstract":"<div><h3>Background</h3><div>The safety of the COVID-19 inactivated vaccine on pregnancy outcomes in couples undergoing assisted reproductive technology remains uncertain due to limited and speculative evidence. Existing studies primarily focus on the vaccination status of females, with scant information available regarding the vaccination status of male partners. Moreover, there is minimal research tracking live birth outcomes.</div></div><div><h3>Objective(s)</h3><div>The objective of this study was to evaluate the impact of COVID-19 inactivated vaccine administration on the outcomes of in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) cycles in infertile couples in China.</div></div><div><h3>Methods</h3><div>This prospective cohort study involved couples undergoing IVF treatment at Sichuan Jinxin Xinan Women &amp; Children’s Hospital from August 2021 to September 2022. Based on whether they received vaccination before ovarian stimulation, the couples were divided into the vaccination group and the non-vaccination group. We compared the laboratory parameters and pregnancy outcomes between the two groups.</div></div><div><h3>Results</h3><div>After performing propensity score matching (PSM), we observed similar live birth rates (41.23% vs. 44.08%, <em>P</em> = 0.555), clinical pregnancy rates (52.61% vs. 54.98%, <em>P</em> = 0.625), biochemical pregnancy (62.56% vs. 63.98%, <em>P</em> = 0.762), and ongoing pregnancy rates (49.76% vs. 51.18%, <em>P</em> = 0.770) between the vaccinated and unvaccinated women. Also, no significant disparities were found in terms of embryo development and laboratory parameters between the groups. Moreover, male vaccination had no impact on patients’ pregnancy outcomes in assisted reproductive technology (ART) treatments (all <em>P</em> &gt; 0.05). Additionally, there were no observable effects of vaccination on embryo development and pregnancy outcomes among couples undergoing ART (all <em>P</em> &gt; 0.05).</div></div><div><h3>Conclusion(s)</h3><div>The findings suggest that COVID-19 vaccination did not have a significant effect on patients undergoing IVF/ICSI with fresh embryo transfer. Therefore, it is recommended that couples should receive COVID-19 vaccination as scheduled to help mitigate the COVID-19 pandemic.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"45 ","pages":"Article 126635"},"PeriodicalIF":4.5,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness of anti-viral treatment for infants with RSV disease in the United Kingdom","authors":"Yonas Gebrecherkos,&nbsp;David Hodgson","doi":"10.1016/j.vaccine.2024.126647","DOIUrl":"10.1016/j.vaccine.2024.126647","url":null,"abstract":"<div><h3>Background</h3><div>Respiratory Syncytial Virus (RSV) is a common cause of hospitalisation in infants worldwide, causing significant morbidity and mortality. Recently, the antiviral treatment, Ziresovir, has shown promising results in a Phase III trial conducted on infants hospitalised with RSV. Based on these topline results, this study aims to investigate the cost-effectiveness of Ziresovir in the United Kingdom (UK).</div></div><div><h3>Methods</h3><div>The cost-effective analysis (CEA) uses a proportional outcomes model using data from topline reports by the AIRFLO trial and published data to explore the effect of Ziresovir administration on hospitalised infants aged &lt;24 months at admission. We estimated the reduction in ICU bed days and deaths and the maximum cost-effective price (MCEP) per treated individual, assuming a threshold of £20,000 per Quality-adjusted Life Year (QALY) gained.</div></div><div><h3>Results</h3><div>Administering Ziresovir to all hospitalised infants averts four deaths (range: 2.8–4.5), 216 ICU admissions (range:160–260) and 3169 ICU bed-days (range: 2348–3804) per annum, the MCEP for Ziresovir per hospitalised infant is £429.65 (95 % CrI: £236–£771). If preterm infants are targeted, then the MCEP increases to £2108.38 (95 % Crl: £870–£3540). The MCEP for exclusively treating Infants with Chronic Lung Disease (CLD) and Congenital Heart Disease (CHD) is £6557.24 (95 % Crl: £1250 - £14,920) and £9459.44 (95 % Crl £3350–£20,300) respectively. The model is highly sensitive to changes in the efficacy of Ziresovir and the risk of ICU admission and mortality.</div></div><div><h3>Conclusion</h3><div>Ziresovir is a cost-effective intervention for all infants hospitalised with RSV if priced below £430 per dose and strategies that exclusively treat high-risk- with CLD and CHD infants justify a higher price of £6558 and £9460 respectively. The outcomes are highly sensitive to the efficacy of Ziresovir and can be improved when the full results of the AIRFLO trial are available.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"45 ","pages":"Article 126647"},"PeriodicalIF":4.5,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142901521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Field vaccination of locally-owned cattle against malignant catarrhal fever under environmentally challenging conditions in Tanzania","authors":"Samuel Bainbridge ,&nbsp;Tauta Mappi ,&nbsp;Sarah Cleaveland ,&nbsp;Choby Chubwa ,&nbsp;Alicia Davis ,&nbsp;Dawn Grant ,&nbsp;Tito Kibona ,&nbsp;Shedrack Bwatota ,&nbsp;Freja Larsen ,&nbsp;Samson Lyimo ,&nbsp;Fadhili Mshana ,&nbsp;Ann Percival ,&nbsp;Gabriel Shirima ,&nbsp;Bakari Mtili ,&nbsp;Felix Jackson Musyangi ,&nbsp;Rigobert Tarimo ,&nbsp;Felix Lankester ,&nbsp;George Russell","doi":"10.1016/j.vaccine.2024.126587","DOIUrl":"10.1016/j.vaccine.2024.126587","url":null,"abstract":"<div><div>Malignant catarrhal fever (MCF), caused by alcelaphine herpesvirus-1 (AIHV-1) transmitted from wildebeest, is a lethal cattle disease with significant impacts on East African pastoralists. Development of a live attenuated MCF vaccine has prompted research into its use in communities at risk. This study reports results from the first utilisation of the MCF vaccine in locally-owned cattle under field conditions. The study involved a primary two-dose course vaccination of 1634 cattle, followed a year later, by boost vaccination of 385 of these cattle. It aimed to: (a) evaluate the antibody response to a two-dose AlHV-1 primary vaccination course, including initial response, antibody levels after one year, and clinical events post-vaccination; (b) assess how factors like age, reproductive status, body condition, and breed influence the initial response; and (c) compare antibody responses to single- and two-dose booster protocols one year after primary vaccination. Analyses were carried out using linear mixed-effects models and paired <em>t</em>-tests.</div><div>Clinical incidents were reported in 11/1634 cattle vaccinated during the primary course and in 0/385 cattle during the boost regimens. The primary vaccination resulted in a 9-fold increase in comparison to pre-vaccination antibody levels and the response was consistent across animals of different ages, reproductive statuses and body conditions. While antibody levels declined 11 months after primary vaccination, they remained high, and a single-dose booster vaccination was sufficient to elicit a strong immune response, with only marginal increases after a second booster.</div><div>The study provides evidence of high immunogenicity and low incidences of clinical events of the vaccine in cattle across individual host factors and immunologically vulnerable groups, under prevailing environmental conditions. It also indicates the utility of a single-dose booster regimen. These findings will support progress towards commercial production and larger-scale adoption which could generate important benefits for the livelihoods, and sustainability of pastoral livestock systems.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"45 ","pages":"Article 126587"},"PeriodicalIF":4.5,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing of rejection events preceded by Covid-19 mRNA vaccination in recipients of solid organ transplants","authors":"Quentin Perrier ,&nbsp;Johan Noble ,&nbsp;Agnès Bonadona ,&nbsp;Caroline Augier ,&nbsp;Thomas Jouve ,&nbsp;Aude Boignard ,&nbsp;Loïc Falque ,&nbsp;Salomé Gallet ,&nbsp;Pierrick Bedouch ,&nbsp;Lionel Rostaing ,&nbsp;Olivier Epaulard ,&nbsp;on behalf of INTEGRAL Study Group","doi":"10.1016/j.vaccine.2024.126617","DOIUrl":"10.1016/j.vaccine.2024.126617","url":null,"abstract":"<div><h3>Objectives</h3><div>SARS-CoV-2 mRNA vaccine reactogenicity has raised concerns regarding the risk of rejection in solid organ transplant recipients. We explored whether SOT recipients diagnosed with acute rejection had previously received a vaccine injection within a timeframe consistent with a causal link.</div></div><div><h3>Methods</h3><div>We identified all SOT recipients with a diagnosis of acute rejection from 2020 to 2022 and who had previously received a SARS-CoV-2 vaccination, and analysed whether the delay between vaccination and rejection was constant.</div></div><div><h3>Results</h3><div>In the 45 identified patients, median delay between the last SARS-CoV-2 vaccination and the rejection was 102 days [IQR 48–178]; the continuous distribution of this delay, with no identifiable time pattern, is not in favor of a role of vaccination in rejection.</div></div><div><h3>Conclusion</h3><div>SARS-CoV-2 mRNA vaccination is unlikely to trigger rejection in SOT recipients.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"45 ","pages":"Article 126617"},"PeriodicalIF":4.5,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laboratory safety and immunogenicity evaluation of live attenuated avian infectious bronchitis GI-23 virus vaccine","authors":"Walid H. Kilany ,&nbsp;Mohamed A. Zain El-Abideen ,&nbsp;Islam Hisham ,&nbsp;Davy Van Gaver ,&nbsp;Abdallah Makahleh ,&nbsp;Isaura Christiaens ,&nbsp;Lise Vlerick ,&nbsp;Magdy F. Elkady","doi":"10.1016/j.vaccine.2024.126659","DOIUrl":"10.1016/j.vaccine.2024.126659","url":null,"abstract":"<div><div>Avian infectious bronchitis virus (IBV) is responsible for a highly contagious disease that poses a significant threat to the poultry industry due to its high rates of evolution. The occurrence of vaccination failure can frequently be attributed to the emergence of novel strains that exhibit antigenic divergence from conventional vaccine strains. This study aims to evaluate the safety and efficacy of the Eg/1212B-based live attenuated virus vaccine indicated for immunization of chickens against nephropathogenic GI-23 variant strains reported globally. Studies were designed in compliance with European Pharmacopeia Ph. Eur. 0442. The attenuated vaccine virus did not exhibit any tendency to revert or increase in virulence after five back-passages in SPF chickens. Ciliostasis scores and kidney lesions (histology) were comparable between vaccinated and control birds. No chicken showed clinical signs of an infection with IBV or died from causes attributable to the vaccine after receiving a 10× overdose. A single vaccination was able to protect the birds in a challenge model with a recent European wild-type IBV strain. The study demonstrated an onset of immunity of 21 days and a duration of immunity lasting up to 56 days. Vaccination administered individually through the ocular route resulted in a protection rate of 100 % to 85 %, whereas mass application by spraying offered a protection rate of 85 % to 80 %. In conclusion, the safety and efficacy data confirm a positive benefit/risk balance, and the investigated product can be considered a suitable vaccine candidate for controlling avian infectious bronchitis nephropathogenic variant strains related to GI-23.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"45 ","pages":"Article 126659"},"PeriodicalIF":4.5,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142900919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic review on the effectiveness of Brucella abortus S19 and RB51 vaccine strains in field studies","authors":"Maysa Serpa Gonçalves ,&nbsp;Marina Martins de Oliveira ,&nbsp;Rafaella Silva Andrade ,&nbsp;Luciana Faria de Oliveira ,&nbsp;Alessandro de Sá Guimarães ,&nbsp;Jacques Godfroid ,&nbsp;Andrey Pereira Lage ,&nbsp;Elaine Maria Seles Dorneles","doi":"10.1016/j.vaccine.2024.126649","DOIUrl":"10.1016/j.vaccine.2024.126649","url":null,"abstract":"<div><div><em>Brucella abortus</em> S19 and RB51 are the most used vaccines to control bovine brucellosis worldwide; therefore, this study aimed to perform a systematic review on the effectiveness of these two vaccine strains in field studies. The literature review was conducted on April 3rd 2020 on six databases (CABI, Cochrane, PubMed, Scielo, Scopus and Web of Science) and included papers published between 1976 and 2016. The search strategy recovered a total of 5846 papers on databases and 6 papers were included due to specialists' suggestions. After selection, 17 papers were included, in which 33 trials were identified. Most trials [63.63 % (21/33)] used prevalence panel design (cross-sectional), while the others were cohort studies. S19 strain was used in most of the trials [75.76 % (25/33)], mainly by subcutaneous route [84.00 % (21/25)] and in adult cattle [76.00 % (19/25)]. RB51 strain was administrated only by the subcutaneous route and in both young and adult animals. For case definition, complement fixation [60.60 % (20/33)] and rivanol [30.30 % (10/33)] were the most used tests. Twenty of the 33 trials (60.61 %) showed significant effect of vaccination on brucellosis control, with lower incidence of infection in the vaccinated groups (in cohort trials) or reduced prevalence after vaccination (in prevalence panels); however, the great heterogeneity observed among the studies precluded a meta-analysis from the data extracted. In addition, most trials [57.57 % (19/33)] adopted other control measures (test-and-slaughter or isolation of positive animals from the herd) in association with vaccination, which harmed the better understand of the isolated effect of vaccination for brucellosis control in field in these studies. In conclusion, the result from this review suggests that both S19 and RB51 vaccine strains are effective in reducing brucellosis incidence in both calves and adults, as well as abortion rates, mainly when associated to other control policies.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"45 ","pages":"Article 126649"},"PeriodicalIF":4.5,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunization and challenge trials in a murine model using different inactivated recombinant vaccines against H1N1 swine influenza virus circulating in Brazil","authors":"Ana Luiza Soares Fraiha ,&nbsp;Beatriz Senra Álvares da Silva Santos ,&nbsp;Nágila Rocha Aguilar ,&nbsp;Grazielle Cossenzo Gallinari ,&nbsp;Ana Luiza Pessoa de Mendonça Angelo ,&nbsp;Julia Machado Caetano Costa ,&nbsp;Paula Angélica Correia ,&nbsp;Lídia Paula Faustino ,&nbsp;Thaís Bárbara de Souza Silva ,&nbsp;Roberto Maurício Carvalho Guedes ,&nbsp;Maria Isabel Maldonado Coelho Guedes ,&nbsp;Alexandre de Magalhães Vieira Machado ,&nbsp;Erica Azevedo Costa ,&nbsp;Zélia Inês Portela Lobato","doi":"10.1016/j.vaccine.2024.126638","DOIUrl":"10.1016/j.vaccine.2024.126638","url":null,"abstract":"<div><div>In Brazil, at least four lineages of influenza A virus circulate pig population: 2009 H1N1 flu pandemic (pH1N1), human-seasonal origin H3N2, H1N1 and H1N2 (huH1 lineages) viruses. Studies related to the occurrence of swine influenza A virus (SIAV) in Brazilian herds have been detecting an increase of occurrence of huH1 lineages. This study aimed to construct recombinant vaccines against the huH1N1 virus and test the immunogens in a murine model. The virus was constructed by reverse genetics using plasmids encoding the HA and NA sequences from a wild huH1N1 virus isolated from an infected pig. Amplified virus was inactivated, and oil-in-water (OW) and gel polymer (GP) adjuvants were used to formulate the vaccines. C57Bl6 mice received two doses with 3 weeks interval by the intramuscular route. Animals were randomly divided into 8 groups (G1-G8): G1 received OW vaccine and G2 PBS plus OW adjuvant; G3 received GP vaccine and G4 PBS plus GP adjuvant; G5 received the live virus by the intranasal route while G6 only PBS; G7 and G8 did not receive any treatment. Serum samples were collected before vaccination and after the first and second dose. Except for G8, three weeks post boost animals were challenged with a wild huH1N1 virus and observed for weight changes. After infection, bronchoalveolar lavage fluid (BALF) and lungs were collected from animals of each group for viral titers and immunohistochemistry (IHC) analysis, respectively. After booster, vaccinated groups seroconverted and the vaccines induced protection upon challenge. Reverse Genetics technique can be used to produce new and quickly updated swine influenza vaccines which is promising to control the virus in Brazilian herds. Future studies may focus on using the technology to produce multivalent recombinant vaccines against distinct strains of SIAVs circulating in Brazilian pig herds.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"45 ","pages":"Article 126638"},"PeriodicalIF":4.5,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seroconversion following PPSV23 vaccination in children with type 1 diabetes mellitus","authors":"Elizabeth Ender ,&nbsp;Avni Joshi ,&nbsp;Melissa Snyder ,&nbsp;Seema Kumar ,&nbsp;Roland Hentz ,&nbsp;Ana Creo","doi":"10.1016/j.vaccine.2024.126592","DOIUrl":"10.1016/j.vaccine.2024.126592","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate whether children with type 1 diabetes mellitus (T1DM) have optimal humoral immune response to pneumococcal polysaccharide vaccination (PPSV23) and to study factors affecting that response.</div></div><div><h3>Methods</h3><div>In this prospective pilot study, we recruited 29 children with T1DM who were vaccine naïve to PPSV23 and assessed serum-serotype specific IgG at baseline and 4–6 weeks post-immunization. We tested association between independent variables (age, gender, body mass index (BMI), hemoglobin A1c (HbA1c), glucose variability, and time in range assessed by continuous glucose monitors (CGM), insulin dose and outcome (log-2-fold change of immunoassay response between pre- and post-immunization testing) using linear regression.</div></div><div><h3>Results</h3><div>Eighty-eight percent of children (22/25) who completed the study had overall appropriate response with a median 4.2-fold change following immunization. When assessing PPSV23-exclusive serotypes, there was a statistically significant correlation between increasing age and greater response (0.16 log2-fold change per year, 95 % CI (0.014 to 0.3), <em>p</em> = 0.033). Higher BMI for age (<em>p</em> = 0.085) and a lower coefficient of glucose variation from CGM following immunization (<em>p</em> = 0.067) also coincided with greater vaccine response, with correlation statistically significant for certain pneumococcal serotypes for both.</div></div><div><h3>Conclusions</h3><div>Response to pneumococcal vaccination has not previously been assessed in children with T1DM, and our study demonstrates robust humoral immune response to PPSV23 vaccination in these children. Larger studies with a diverse representation and longer follow up to assess how humoral seroconversion correlates with clinical response to PPSV23 in this vulnerable population are warranted.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"45 ","pages":"Article 126592"},"PeriodicalIF":4.5,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Left out in the cold - inequity in infectious disease control due to cold chain disparity","authors":"Aimee Talbot ,&nbsp;Tania F. de Koning-Ward ,&nbsp;Daniel Layton","doi":"10.1016/j.vaccine.2024.126648","DOIUrl":"10.1016/j.vaccine.2024.126648","url":null,"abstract":"<div><div>Vaccines and diagnostic tools stand out as among the most influential advancements in public health, credited with averting an estimated 6 million deaths annually and substantially alleviating the burden of infectious disease. Despite this progress, the global imperative to prevent, detect, and combat infectious disease persists. Regrettably, hundreds of thousands of lives are still lost due to inadequate access to vaccines and diagnostics. A critical obstacle in accessibility lies in the requirement of reliable cold chain for their transportation and storage, a resource that remains inadequate in many regions, particularly in the developing world. Various factors, including socio-economic disparities, biological complexities, and manufacturing processes, exert significant influence on the availability and integrity of vaccines and diagnostic materials. This review aims to explore the multifaceted issue of inequality in access to disease control tools, examining the vulnerabilities of vaccines and diagnostics while also investigating recent advancements that offer promising solutions to improve thermal stability.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"45 ","pages":"Article 126648"},"PeriodicalIF":4.5,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}